Abstract
The heat shock protein (Hsp) family is an evolutionarily conserved system that is charged with preventing unfolded or misfolded proteins in the cell from aggregating. In Alzheimers disease, extracellular accumulation of the amyloid β peptide (Aβ) and intracellular aggregation of the microtubule associated protein tau may result from mechanisms involving chaperone proteins like the Hsps. Due to the ability of Hsps to regulate aberrantly accumulating proteins like Aβ and tau, therapeutic strategies are emerging that target this family of chaperones to modulate their pathobiology. This article focuses on the use of Hsp-based therapeutics for treating primary and secondary tauopathies like Alzheimers disease. It will particularly focus on the pharmacological targeting of the Hsp70/90 system and the value of manipulating Hsp27 for treating Alzheimers disease.
Keywords: Heat shock proteins, chaperones, neurodegeneration, alzheimer, Hsp27, Tau, heat shock proteins (Hsps), 42-amino acid version, Alzheimer's disease
Current Neuropharmacology
Title: Exploiting the Diversity of the Heat-Shock Protein Family for Primary and Secondary Tauopathy Therapeutics
Volume: 9 Issue: 4
Author(s): Jose F. Abisambra, Umesh K. Jinwal, Jeffrey R. Jones, Laura J. Blair, John Koren III and Chad A. Dickey
Affiliation:
Keywords: Heat shock proteins, chaperones, neurodegeneration, alzheimer, Hsp27, Tau, heat shock proteins (Hsps), 42-amino acid version, Alzheimer's disease
Abstract: The heat shock protein (Hsp) family is an evolutionarily conserved system that is charged with preventing unfolded or misfolded proteins in the cell from aggregating. In Alzheimers disease, extracellular accumulation of the amyloid β peptide (Aβ) and intracellular aggregation of the microtubule associated protein tau may result from mechanisms involving chaperone proteins like the Hsps. Due to the ability of Hsps to regulate aberrantly accumulating proteins like Aβ and tau, therapeutic strategies are emerging that target this family of chaperones to modulate their pathobiology. This article focuses on the use of Hsp-based therapeutics for treating primary and secondary tauopathies like Alzheimers disease. It will particularly focus on the pharmacological targeting of the Hsp70/90 system and the value of manipulating Hsp27 for treating Alzheimers disease.
Export Options
About this article
Cite this article as:
F. Abisambra Jose, K. Jinwal Umesh, R. Jones Jeffrey, J. Blair Laura, Koren III John and A. Dickey Chad, Exploiting the Diversity of the Heat-Shock Protein Family for Primary and Secondary Tauopathy Therapeutics, Current Neuropharmacology 2011; 9 (4) . https://dx.doi.org/10.2174/157015911798376226
DOI https://dx.doi.org/10.2174/157015911798376226 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Potential Role of Sirtuins Regarding the Effects of Exercise on Aging- Related Diseases
Current Aging Science Molecular Imaging: Its Application In Cardiovascular Diagnosis
Current Pharmaceutical Design Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets CypD: The Key to the Death Door
CNS & Neurological Disorders - Drug Targets Structure, Production and Function of Erythropoietin: Implications for Therapeutical Use in Cardiovascular Disease
Current Medicinal Chemistry Does More MnSOD Mean More Hydrogen Peroxide?
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issues: Pharmacological Mechanisms and Interventions in Ischemia/ Reperfusion-Induced Injury)
Current Pharmaceutical Design Evaluation of Eudragit® Retard Polymers for the Microencapsulation of Alpha-Lipoic Acid
Current Drug Delivery Isolation, Characterization and Hypoglycemic Activity of an Acid Polysaccharide Isolated from Schisandra chinensis (Turcz.) Baill
Letters in Organic Chemistry Ethyl Pyruvate: A Novel Treatment for Sepsis
Current Drug Targets Tetramethylpyrazine Facilitates Functional Recovery after Spinal Cord Injury by Inhibiting MMP2, MMP9, and Vascular Endothelial Cell Apoptosis
Current Neurovascular Research Adenosine A2A Receptor Antagonists and Parkinsons Disease: State of the Art and Future Directions
Current Pharmaceutical Design An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases
Mini-Reviews in Medicinal Chemistry Polyphenols: Well Beyond The Antioxidant Capacity: Polyphenol Supplementation and Exercise-Induced Oxidative Stress and Inflammation
Current Pharmaceutical Biotechnology The Role of Oxidative Stress Modulators in Breast Cancer
Current Medicinal Chemistry Immune-Mediated Mechanisms in Atherosclerosis: Prevention and Treatment of Clinical Manifestations
Current Pharmaceutical Design Emerging Role for Antioxidant Therapy in Protection Against Diabetic Cardiac Complications: Experimental and Clinical Evidence for Utilization of Classic and New Antioxidants
Current Cardiology Reviews Empagliflozin and the Diabetic Kidney: Pathophysiological Concepts and Future Challenges
Endocrine, Metabolic & Immune Disorders - Drug Targets A Concept of Homeostatic Inflammation Provided by Endogenous TLR4 Agonists that Function Before and After Danger Signal for Metastasis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cannabinoid System in Neurodegeneration: New Perspectives in Alzheimers Disease
Mini-Reviews in Medicinal Chemistry